Completes the multi-billion-dollar, value accretive transaction in part-equity and part-cash, including: Upfront cash payment of USD 2 billion Issuance of CCPS worth USD 1 billion Creates a unique, fully integrated, leading global biosimilars enterprise with eight commercialized products Accelerates direct commercialization of…